Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and Subjects With Impaired Renal Function.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2013
At a glance
- Drugs PB 1023 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 12 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 Jun 2012 Planned end date changed from 1 Feb 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.